Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
Authors' conclusion
Treatment effects of iGlarLixi were consistent irrespective of baseline HbA1c, insulin dose, BMI, age, duration of diabetes and renal function, supporting the use of iGlarLixi as an efficacious and well-tolerated treatment option in people with type 2 diabetes with a wide range of biomedical characteristics.
Study context
- Population
- People with T2D in SoliMix, analysed by baseline age, diabetes duration, insulin dose, HbA1c, body mass index (BMI) and renal function
- Comparison
- Once-daily iGlarLixi vs twice-daily BIAsp 30
- Primary endpoint
- Original primary outcomes (noninferiority in HbA1c change, superiority in body weight change), with basal insulin dose change and hypoglycaemia outcomes, by baseline subgroups
Methodological detailsprespecified and post hoc subgroup analyses
- Prespecified and post hoc subgroup analyses
Primary result
As reported in the abstract
Heterogeneity of comparative treatment effect across baseline subgroups
- No evidence of difference in comparative treatment effect across baseline age, diabetes duration, insulin dose, HbA1c, BMI and renal function subgroups for any endpoint
- all heterogeneity P > 0.05
- Exception: ADA Level 2 hypoglycaemia event rate stratified by insulin dose; may be chance given multiple testing and small numbers of Level 2 events
- P = 0.011
Original publication
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. Diabetes Obes Metab. Published 23 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →